ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
Characterization of Dronabinol Usage in a Pediatric Oncology Population.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Cannabinoids for Medical Purposes in Children: A Living Systematic Review.Acta paediatrica (Oslo, Norway : 1992) · 2025Pooled it
- Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis.Current oncology reports · 2025Pooled it
- Pharmacological evidence of medicinal cannabis in oncology: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Pooled it
- Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.Neurology · 2019Guideline
- The Role of Cannabinoids and the Endocannabinoid System in the Treatment and Regulation of Nausea and Vomiting.Current topics in behavioral neurosciences · 2026Review
- Under the Influence: Cognitive Effects of Medical Marijuana on Developing Minds.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Exploring the therapeutic potential of cannabinoids in cancer by modulating signaling pathways and addressing clinical challenges.Discover oncology · 2024Review
- Anti-Emetics in Children Receiving Chemotherapy for Solid Tumors and Leukemia: Pharmacology and Optimization of Therapy for Nausea and Vomiting.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Cannabis with breast cancer treatment: propitious or pernicious?3 Biotech · 2022Article
- Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer.Journal of adolescent and young adult oncology · 2021Article
- Review
- Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome.Medical cannabis and cannabinoids · 2019Article
- Medical Cannabis Certification in a Large Pediatric Oncology Center.Children (Basel, Switzerland) · 2019Article
- Medicinal Cannabis-Potential Drug Interactions.Medicines (Basel, Switzerland) · 2018Review
- Medical Use of Cannabinoids.Drugs · 2018Review
- Article
- Cannabinoid Regulation of Acute and Anticipatory Nausea.Cannabis and cannabinoid research · 2016Review
- Cannabis Use for Therapeutic Purposes by Children and Youth at a Tertiary Teaching Hospital in Canada: A Retrospective Chart Review.The Canadian journal of hospital pharmacyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesChemotherapy-induced nausea and vomiting (CINV) remains an important side effect associated with administration of chemotherapy in pediatrics. The aim of this study was to retrospectively review dronabinol use in a pediatric cancer center, with the intent of characterizing its use and identifying trends such as age, sex, diagnosis, and chemotherapy that describe where dronabinol is best used as an adjuvant antiemetic.
methodsPatients receiving dronabinol at Riley Hospital for Children between 2000 and 2010 were identified. Patients eligible for inclusion were those with malignancy ≤18 years old, who received at least 1 dose of dronabinol for CINV during admission.
resultsNinety-five percent of patients received moderate or highly emetogenic chemotherapy. When dronabinol doses were analyzed, 95% of patients received doses that were lower than reference guidelines, 55% received dronabinol as a scheduled medication, and 19% received dronabinol 1 to 3 hours before chemotherapy. Overall, 60% of patients had a defined positive response to dronabinol. Sixty-five percent of patients received repeat courses of dronabinol, and 62% received outpatient prescriptions for dronabinol.
conclusionsDronabinol appears to be a viable option as an adjuvant antiemetic in pediatric CINV, but a prospective trial using patients as their own controls is necessary to truly define dronabinol's place in therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.